
Search Clinical Trials
| Sponsor Condition of Interest |
|---|
|
The Impact of Cobenfy Maintenance on Cocaine's Effects
Joshua A. Lile, Ph.D.
Cocaine Use Disorder (CUD)
The goal of this clinical trial is to learn if Cobenfy influences the effects of cocaine
in people with cocaine use disorder. This trial will also provide information about the
safety and tolerability of combining Cobenfy and cocaine.
Researchers will compare Cobenfy to a placebo (a look-alike sub1 expand
The goal of this clinical trial is to learn if Cobenfy influences the effects of cocaine in people with cocaine use disorder. This trial will also provide information about the safety and tolerability of combining Cobenfy and cocaine. Researchers will compare Cobenfy to a placebo (a look-alike substance that contains no drug) to see if Cobenfy is a safe, tolerable and effective at blocking cocaine's effects in participants with cocaine use disorder. Participants will: - Participate in an 11-day inpatient trial - Take Cobenfy or placebo twice per day. - Participate in experimental sessions to test the effects of Cobenfy (or placebo) on the response to cocaine and cocaine self-administration. Type: Interventional Start Date: Aug 2026 |
|
Comparing Acupuncture vs. Sham Acupuncture for the Management of Hot Flashes in Prostate Cancer Pat1
University of Kentucky
Accupuncture
Prostate Cancer
Hormone Therapy
Hot Flashes
This study is evaluating whether acupuncture may help reduce hot flashes in men receiving
hormone therapy for prostate cancer. Hot flashes are a common side effect of androgen
deprivation therapy (ADT) and may negatively affect sleep, mood, concentration, daily
activities, and overall quality of li1 expand
This study is evaluating whether acupuncture may help reduce hot flashes in men receiving hormone therapy for prostate cancer. Hot flashes are a common side effect of androgen deprivation therapy (ADT) and may negatively affect sleep, mood, concentration, daily activities, and overall quality of life. Participants enrolled in this study will receive acupuncture treatment over a defined treatment period. The study will assess changes in hot flash frequency, severity, and quality of life using patient questionnaires and symptom diaries. Participants will complete a daily hot flash diary during selected 7-day assessment periods and quality-of-life questionnaires during study visits. The primary goal of this study is to determine whether acupuncture may improve hot flash symptoms and related quality of life in men undergoing treatment for prostate cancer. Type: Interventional Start Date: Aug 2026 |
|
Phase 2 Study to Assess the Safety and Efficacy of ANG003
Anagram Therapeutics, Inc.
Exocrine Pancreatic Insufficiency (EPI)
Cystic Fibrosis (CF)
In this study, ANG003, a pancreatic enzyme replacement therapy (PERT; commonly called
"enzymes"), is being investigated as a potential treatment for exocrine pancreatic
insufficiency (EPI). People with EPI due to Cystic Fibrosis (CF) may be eligible to
participate in this study. The primary objecti1 expand
In this study, ANG003, a pancreatic enzyme replacement therapy (PERT; commonly called "enzymes"), is being investigated as a potential treatment for exocrine pancreatic insufficiency (EPI). People with EPI due to Cystic Fibrosis (CF) may be eligible to participate in this study. The primary objective of this study is to evaluate the safety of ANG003 and see if it works as well compared to Creon, an approved PERT. Type: Interventional Start Date: Apr 2026 |
|
Rapid Evacuation and Access of Cerebral Hemorrhage Trial
Emory University
Stroke Hemorrhagic
The main purpose of this study is to compare patients with a deep bleed in the brain
undergoing surgery to patients receiving routine medical care. The standard treatment
involves admission to the Intensive Care Unit (ICU) with close monitoring and blood
pressure control. It also includes other med1 expand
The main purpose of this study is to compare patients with a deep bleed in the brain undergoing surgery to patients receiving routine medical care. The standard treatment involves admission to the Intensive Care Unit (ICU) with close monitoring and blood pressure control. It also includes other medical (non-surgical) treatments to prevent more bleeding or another stroke. Sometimes, doctors will recommend surgery to remove the blood if medical treatment alone is not successful. There is evidence that doing minimally invasive surgery early-using a small opening in the skull to remove blood-may help some patients. Researchers aim to understand whether this surgery is better than current medical treatment, which may include surgeries to relieve pressure on the brain in some cases. This study, called REACH, is comparing usual medical care to early minimally invasive surgery so doctors can know which is better for patients. Type: Interventional Start Date: May 2025 |
|
A Study of Patients With Lower Extremity Acute Limb Ischemia to Remove Thrombus With the Indigo™ As1
Penumbra Inc.
Lower Extremity Acute Limb Ischemia
LE ALI
The primary objective of this study is to collect and evaluate clinical evidence
supporting the safety and performance of the Indigo™ Aspiration System in a patient
population with lower extremity acute limb ischemia (LE ALI). expand
The primary objective of this study is to collect and evaluate clinical evidence supporting the safety and performance of the Indigo™ Aspiration System in a patient population with lower extremity acute limb ischemia (LE ALI). Type: Observational Start Date: May 2025 |
|
A Study of Vosoritide in Children With Noonan Syndrome With Inadequate Growth During or After Human1
BioMarin Pharmaceutical
Noonan Syndrome
The purpose of this study in children with Noonan syndrome is to evaluate the effect of 3
doses of vosoritide on growth as measured by AGV after 6 months of treatment. The
long-term efficacy and safety of vosoritide at the therapeutic dose will be evaluated up
to FAH. expand
The purpose of this study in children with Noonan syndrome is to evaluate the effect of 3 doses of vosoritide on growth as measured by AGV after 6 months of treatment. The long-term efficacy and safety of vosoritide at the therapeutic dose will be evaluated up to FAH. Type: Interventional Start Date: Nov 2024 |
|
Trial of the Efficacy and Safety of Short and Long Course Radiation Therapy With/Without BMX-001
University of Nebraska
Rectal Cancer
In this Phase 2 study, we will conduct an efficacy and safety study of the combination of
investigational drug BMX-001, with short-course radiotherapy (SCRT) or long-course
chemoradiotherapy (LCCRT) as part of total neoadjuvant therapy in newly diagnosed rectal
adenocarcinoma (RAC) patients. expand
In this Phase 2 study, we will conduct an efficacy and safety study of the combination of investigational drug BMX-001, with short-course radiotherapy (SCRT) or long-course chemoradiotherapy (LCCRT) as part of total neoadjuvant therapy in newly diagnosed rectal adenocarcinoma (RAC) patients. Type: Interventional Start Date: Aug 2022 |
|
Gamification Effects on the 6-Minute Walk Test in Children
David Toupin
Neuromuscular Diseases in Children
The goal of this study is to learn if adding a game to the 6-minute walk test for
children with neuromuscular disorders will increase enjoyment and motivation to complete
the test. expand
The goal of this study is to learn if adding a game to the 6-minute walk test for children with neuromuscular disorders will increase enjoyment and motivation to complete the test. Type: Interventional Start Date: Jun 2026 |
|
Mitigation of Cardiovascular Disease Risks in Children With Extreme Obesity
John Bauer
Obesity and Overweight
Obese Adolescents
Weight Management
Weight Loss
Cardiovascular Disease Risk Factor
The goal of this clinical trial is to learn if the drug semaglutide changes markers of
disease risk as it relates to weight in children ages 12-15 years old who are obese
(class 2 or 3). The main questions it aims to answer are:
- How do the rate of weight loss, body mass index (BMI), body comp1 expand
The goal of this clinical trial is to learn if the drug semaglutide changes markers of disease risk as it relates to weight in children ages 12-15 years old who are obese (class 2 or 3). The main questions it aims to answer are: - How do the rate of weight loss, body mass index (BMI), body composition, heart structure and function, and exercise ability interact with one another in the study population at enrollment? - How do risk markers of disease change over the study in the study participants who are given semaglutides to help with weight loss? - Are there differences in the above factors between males and females and are there key factors to help improve the outcomes? Participants will be given semaglutide for this study. During the course of the study, participants will: - have two cardiac MRI scans OR two cardiac echocardiograms (one before starting semaglutide and one around 12 months after taking the drug) - have body composition and fitness levels assessed twice (before semaglutide and around 12 months after taking it) and have urine specific gravity (USG) measured - have extra blood drawn when labs their doctor orders are already being drawn (once at the beginning of the study, once around 6 months after enrollment, and once at the end of the study) - have follow up visits with the study doctor - be asked to take a pregnancy test if they are female and have started menstruation Type: Observational Start Date: Jun 2025 |
|
Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Inter1
Tempus AI
Pulmonary Hypertension
Interstitial Lung Disease (ILD)
MOMENTOUS is a multi-center, randomized study to prospectively evaluate the performance
of an ECG-based AI device to predict whether participants with interstitial lung disease
(ILD) are at high risk of undiagnosed pulmonary hypertension. expand
MOMENTOUS is a multi-center, randomized study to prospectively evaluate the performance of an ECG-based AI device to predict whether participants with interstitial lung disease (ILD) are at high risk of undiagnosed pulmonary hypertension. Type: Interventional Start Date: Jul 2025 |
|
Improving Behavioral Health for Caregivers and Children After Pediatric Injury
Medical University of South Carolina
Quality of Life
PTSD
Depression Not Otherwise Specified
Child Externalizing Behavior
Pediatric traumatic injury (PTI) is a public health priority, with more than 125,000
children experiencing injuries that require hospitalization each year. These children,
and their caregivers, are affected in many ways that may affect quality of life,
emotional and behavioral health, physical reco1 expand
Pediatric traumatic injury (PTI) is a public health priority, with more than 125,000 children experiencing injuries that require hospitalization each year. These children, and their caregivers, are affected in many ways that may affect quality of life, emotional and behavioral health, physical recovery, family roles and routines, and academic functioning; yet US trauma centers do not adequately address these outcomes and a scalable national model of care for these families is needed. This proposal builds on prior research from the investigative team to test a technology-assisted, stepped care behavioral health intervention for children (<12 years) and their caregivers after PTI, CAARE (Caregivers' Aid to Accelerate Recovery after pediatric Emergencies), via a hybrid type I effectiveness-implementation trial with 348 families randomly assigned to CAARE (n=174) vs. guideline-adherent enhanced usual care (EUC) (n=174). Type: Interventional Start Date: May 2025 |
|
A Phase Ib Study of VK-2019 in Patients With Relapsed or Refractory EBV+ Diffuse Large B-cell Lymph1
Pierluigi Porcu
Diffuse Large B Cell Lymphoma Refractory
Diffuse Large B Cell Lymphoma Relapsed
Epstein-Barr Virus (EBV) Infection
This is a Phase Ib in adult patients with relapsed or refractory EBV-positive DLBCL using
daily oral dosing of VK-2019 in three dose escalation cohorts: 600 mg/day, 1200 mg/day,
1800 mg/day for 28 days (cycle), until progression or toxicity. expand
This is a Phase Ib in adult patients with relapsed or refractory EBV-positive DLBCL using daily oral dosing of VK-2019 in three dose escalation cohorts: 600 mg/day, 1200 mg/day, 1800 mg/day for 28 days (cycle), until progression or toxicity. Type: Interventional Start Date: Aug 2026 |
|
Evaluating Safety and Feasibility of Transcutaneous Spinal Cord Stimulation Following Traumatic and1
Francis Farhadi
Spinal Cord Stimulation
Electric Stimulation Therapy
Traumatic Spinal Cord Injury
Cervical Myelopathy
The study will be a non-randomized, non-blinded pilot study to analyze the safety and
feasibility of a non-significant risk device, transcutaneous spinal cord stimulation. The
aim is to include 30 total patients, 10 patients in each of 3 groups:
1. Non-traumatic spinal cord injury (ntSCI) with d1 expand
The study will be a non-randomized, non-blinded pilot study to analyze the safety and feasibility of a non-significant risk device, transcutaneous spinal cord stimulation. The aim is to include 30 total patients, 10 patients in each of 3 groups: 1. Non-traumatic spinal cord injury (ntSCI) with diagnosis of degenerative cervical myelopathy and offered surgical intervention. 2. Early tSCI screened during the hospital admission when cervical/thoracic spinal injury was diagnosed. 3. Delayed tSCI (control) screened 6-24 months after acute cervical/thoracic spinal injury. Type: Interventional Start Date: Oct 2024 |
|
Creating VIP Corps to Reduce Maternal Deaths
Ann Coker
Maternal Morbidity and Mortality
The goal of this observational study is to create and rigorously evaluate a violence
intervention and prevention corps (VIP Corps) training using a randomized controlled
trial among undergraduate and professional students; and to develop a novel maternal
injury surveillance system (MISS) to complem1 expand
The goal of this observational study is to create and rigorously evaluate a violence intervention and prevention corps (VIP Corps) training using a randomized controlled trial among undergraduate and professional students; and to develop a novel maternal injury surveillance system (MISS) to complement an existing maternal violent death registry in Kentucky. Type: Interventional Start Date: Sep 2023 |
|
Prospective Evaluation of Pathways for Preterm Birth
John O'Brien, MD
Preterm Birth
Cervix; Pregnancy
This is a single center, prospective cohort study of pregnant patients at high risk for
spontaneous preterm birth: patient's with history of spontaneous preterm birth, patient's
with a short cervix and patient's symptomatic for preterm birth will be included. A
control cohort of nulliparous patient1 expand
This is a single center, prospective cohort study of pregnant patients at high risk for spontaneous preterm birth: patient's with history of spontaneous preterm birth, patient's with a short cervix and patient's symptomatic for preterm birth will be included. A control cohort of nulliparous patients without a short cervix will be recruited to provide baseline data. Plan to enroll 240 patients identified through our ultrasound unit with goal of 60 patients in each group. Type: Observational Start Date: Feb 2022 |
|
A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants W1
Neuron23 Inc.
Parkinson Disease
Parkinson
Idiopathic Parkinson Disease
Early Parkinson Disease (Early PD)
Parkinson Disease, Idiopathic
The goal of this Phase 2 clinical trial is to investigate the efficacy and safety of
NEU-411 in men and women aged 40-80 years with early Parkinson's Disease (PD) who have
predicted elevations in the activity of the "leucine-rich repeat kinase 2" ("LRRK2" for
short) pathway based on their genetic p1 expand
The goal of this Phase 2 clinical trial is to investigate the efficacy and safety of NEU-411 in men and women aged 40-80 years with early Parkinson's Disease (PD) who have predicted elevations in the activity of the "leucine-rich repeat kinase 2" ("LRRK2" for short) pathway based on their genetic profile. A DNA test will be used to identify the "LRRK2-driven" population with predicted elevation in the LRRK2 pathway. Type: Interventional Start Date: Jan 2025 |
|
Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advan1
Abbott Medical Devices
Heart Failure
Heart Diseases
Cardiovascular Diseases
Pulmonary Hypertension
The purpose of TEAM-HF IDE clinical trial is to evaluate safety and effectiveness of the
HeartMate 3 LVAS compared to guideline directed medical therapy (GDMT) in a population of
ambulatory advanced heart failure patients who are not dependent on intravenous inotrope. expand
The purpose of TEAM-HF IDE clinical trial is to evaluate safety and effectiveness of the HeartMate 3 LVAS compared to guideline directed medical therapy (GDMT) in a population of ambulatory advanced heart failure patients who are not dependent on intravenous inotrope. Type: Interventional Start Date: Dec 2024 |
|
Muscle Recovery After Critical Illness
Esther Dupont-Versteegden
ICU Acquired Weakness
Post Intensive Care Unit Syndrome
Muscle Weakness
Critical Illness
The overarching goal of the proposed study is to determine the trajectories of physical
recovery and cellular markers involved with the underlying failure to recover muscle
after critical illness, while exploring which characteristics are associated with
sustained physical disability. This proposal1 expand
The overarching goal of the proposed study is to determine the trajectories of physical recovery and cellular markers involved with the underlying failure to recover muscle after critical illness, while exploring which characteristics are associated with sustained physical disability. This proposal will examine muscle pathophysiology carefully aligned with physical function outcomes in order to longitudinally assess the recovery, or failed recovery, of muscle function in participants after critical illness: 1. to examine the recovery of muscle and physical function in ICU survivors through longitudinal assessments 2. to investigate the underlying cellular markers and mechanisms of muscle recovery in ICU survivors 3. to determine which cellular markers contribute to physical disability in ICU survivors up to 1 year after hospital admission Type: Observational Start Date: Oct 2022 |
|
Bromelain for Post-surgery Facial Swelling
Mohamed Bazina
Malocclusion
The goal of this clinical trial is to learn if Bromelain Supplement works to decrease the
amount of swelling or the amount of time swelling is present following jaw surgery. It
will also learn about the safety of Bromelain supplement. The main questions it aims to
answer are:
Does Bromelain decrea1 expand
The goal of this clinical trial is to learn if Bromelain Supplement works to decrease the amount of swelling or the amount of time swelling is present following jaw surgery. It will also learn about the safety of Bromelain supplement. The main questions it aims to answer are: Does Bromelain decrease facial swelling following orthognathic, or jaw, surgery? Does Bromelain supplement decrease the amount of time that patients are swollen following orthognathic, or jaw, surgery? Participants will: Take Bromelain supplement once daily for 9 days total. Take 2 days before surgery and 7 days following surgery. Keep a log of when the bromelain supplement is taken as well as another other medications. Visit the clinic with pre and post surgical protocol Type: Interventional Start Date: Sep 2025 |
|
A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)
Vor Biopharma
Generalized Myasthenia Gravis
The purpose of this study is to evaluate the efficacy and safety of telitacicept in the
treatment of generalized myasthenia gravis. expand
The purpose of this study is to evaluate the efficacy and safety of telitacicept in the treatment of generalized myasthenia gravis. Type: Interventional Start Date: Jul 2024 |
|
Vivistim Registry for Paired VNS Therapy (GRASP)
MicroTransponder Inc.
Upper Extremity Problem
The purpose of the Vivistim Registry for Paired VNS Therapy (GRASP) is to gather
real-world information on patients with arm and hand deficits post-stroke who are
considering Vivistim System treatment. Before and after Vivistim System implant, patient
data will be collected and reported throughout1 expand
The purpose of the Vivistim Registry for Paired VNS Therapy (GRASP) is to gather real-world information on patients with arm and hand deficits post-stroke who are considering Vivistim System treatment. Before and after Vivistim System implant, patient data will be collected and reported throughout the therapy process. Physicians or sites will receive appropriate remuneration for the effort and cost involved in collecting and transmitting this data to MicroTransponder Inc. Type: Observational [Patient Registry] Start Date: Mar 2023 |
|
REmotely Monitored, Mobile Health Supported Multidomain Rehabilitation Program With High Intensity1
Duke University
COVID-19
Critical Illness
ICU Acquired Weakness
PICS
Cardiorespiratory Fitness
Multicenter, prospective, randomized controlled trial providing mobile health supported
physical rehabilitation to 120 patients who have been critically ill with COVID-19 and
who complete at least one exercise session. expand
Multicenter, prospective, randomized controlled trial providing mobile health supported physical rehabilitation to 120 patients who have been critically ill with COVID-19 and who complete at least one exercise session. Type: Interventional Start Date: Feb 2023 |
|
Multisite Inventory of Neonatal-Perinatal Interventions (MINI) Minimum Dataset
The University of Texas Health Science Center, Houston
Infant, Extremely Premature
Obstetric Labor, Premature
Premature Birth
Intensive Care, Neonatal
Intensive Care Units, Neonatal
The goal of the Tiny Baby Collaborative Multicenter Inventory of Neonatal-Perinatal
Interventions (MINI) minimum dataset is to serve as a registry detailing the outcomes and
practices for all deliveries and infants admitted to intensive care at 22-23 weeks'
gestation at participating hospitals. expand
The goal of the Tiny Baby Collaborative Multicenter Inventory of Neonatal-Perinatal Interventions (MINI) minimum dataset is to serve as a registry detailing the outcomes and practices for all deliveries and infants admitted to intensive care at 22-23 weeks' gestation at participating hospitals. Type: Observational [Patient Registry] Start Date: Jan 2019 |
|
Autologous suraL nervE Grafting to the Substantia nigrA in Patients With Synuclienopathies
Craig van Horne, MD, PhD
Multiple System Atrophy
Parkinsons Disease
This phase I double-blind study focuses on the safety and feasibility of implanting
autologous peripheral nerve tissue (PNT) into the substantia nigra area of the brain in
persons who have been diagnosed with either Parkinson's disease (PD) or Multiple System
Atrophy (MSA). 7 participants will be e1 expand
This phase I double-blind study focuses on the safety and feasibility of implanting autologous peripheral nerve tissue (PNT) into the substantia nigra area of the brain in persons who have been diagnosed with either Parkinson's disease (PD) or Multiple System Atrophy (MSA). 7 participants will be enrolled, with 4 participants receiving the graft and 3 receiving a sham surgery. Eligible participants will be early in their diagnosis with a lower burden of symptoms. Participants will be followed initially for one year after surgery. Type: Interventional Start Date: Feb 2025 |
|
Investigation of the BrioVAD System for the Treatment of Left Ventricular Heart Failure
BrioHealth Solutions, Inc.
Cardiovascular Diseases
Heart Diseases
Heart Failure
The goal of this study is to evaluate the safety and efficacy of the BrioVAD System by
demonstrating non-inferiority to the HeartMate 3 Left Ventricular Assist System when used
for the treatment of advanced, refractory, left ventricular heart failure. expand
The goal of this study is to evaluate the safety and efficacy of the BrioVAD System by demonstrating non-inferiority to the HeartMate 3 Left Ventricular Assist System when used for the treatment of advanced, refractory, left ventricular heart failure. Type: Interventional Start Date: Oct 2024 |